ETFIQData as of Nov 19, 2026. · etfiq.com/funds/bbp

BBP Fact Sheet: Virtus Biotech ETF

Share
$94.51
close, Nov 20, 2026

Over the year to Nov 19, 2026, BBP returned +27.4% in total and charged 0.34% a year.

1-year total return
+25.5%
to Nov 20, 2026
Expense ratio
0.34%
a year
Net assets
$126m
on Nov 19, 2026
Net flow, last 4 trading days
$0
daily basis to Nov 19, 2026

Growth of $10,000, 1 year

BBP $12,739 +27.4% · Total return, distributions reinvested, Nov 19, 2025 to Nov 19, 2026.

Returns

WindowTotal return
1 month−9.9%
3 months−12.1%
Year to date+18.3%
1 year+25.5%
3 years+93.3%
5 years+92.5%

Total return, distributions reinvested, each window to Nov 20, 2026.

Ten largest positions

HoldingWeight
CRINETICS PHARMACEUTICALS INC3.34%
KINIKSA PHARMACEUTICALS INTERNATIONAL PLC1.97%
VERASTEM INC1.95%
PRECIGEN INC1.94%
OMEROS CORP1.87%
NUVATION BIO INC1.77%
REGENERON PHARMACEUTICALS1.72%
PROTAGONIST THERAPEUTICS INC1.71%
ACADIA PHARMACEUTICALS INC1.69%
BRIDGEBIO PHARMA INC1.65%

BBP top ten by weight, 19.6% of the fund, of its 67 equity positions, from the holdings filed for Jul 31, 2026.

Facts

Holds 67 stocks in biotech, 10% of its weight in S&P 500 companies · First traded Dec 17, 2014 · Benchmark Its own holdings, as of Jul 31, 2026

Source: ETFIQ, from issuer disclosures, SEC filings and exchange prices. Returns from daily closes, distributions reinvested; each number is dated beside it, and every one is on the fund’s page.Cite as: ETFIQ, BBP Fact Sheet: Virtus Biotech ETF. Data as of Nov 19, 2026. https://etfiq.com/funds/bbp/fact-sheet/ETFIQ is an independent publisher. Not an issuer, broker or adviser. No recommendations. Printed from etfiq.com/funds/bbp.